Abstract

Raynaud’s Phenomenon (RP) serves as the clinical sentinel for systemic autoimmunity, frequently predating connective tissue disease diagnosis by years. While RP is a largely benign functional vasospasm in the general population, its prevalence in Systemic Sclerosis (SSc) approaches 99%. A fundamental mystery in Rheumatology is the divergent fate of the microvasculature across connective tissue diseases. RP can occur in other autoimmune diseases; it is usually not associated with the relentless transition to obliterative vasculopathy. In SSc, the vessel lumen is physically occluded by intimal proliferation and perivascular fibrosis, yet the mechanism triggering this ischemia remains poorly understood. Beyond the classic tri-phasic color change, SSc patients frequently report other early distressing sensory symptoms, specifically intense pruritus, neuropathic burning, and profound edema. Historically dismissed as secondary to ischemia, we propose that these sensations are primary markers of the underlying pathological driver. We challenge the traditional B-cell/T-cell-centric view of SSc by introducing the concept of autoallergy. We hypothesize that these sensory symptoms represent chronic, IgE-mediated activation of resident mast cells. This mast cell-driven circuit, triggered by SSc-specific autoantigens, acts as a persistent secretory pump for pro-fibrotic cytokines, fundamentally distinguishing SSc vasculopathy from the purely inflammatory vascular patterns seen in other connective tissue diseases. Targeting the IgE–mast cell axis early in the course of the disease may offer a novel therapeutic window to halt the transition from functional vasospasm to permanent structural obliteration.

IPC Classification

Keywords